NICE turns down AZ’ Faslodex for breast cancer

1st September 2017 Uncategorised 0

It is looking unlikely that AstraZeneca’s breast cancer drug Faslodex will be routinely funded on the NHS to delay growth of a specific type of breast cancer, after cost regulators concluded that its benefit over existing therapies has not been shown at this time.

More: NICE turns down AZ’ Faslodex for breast cancer
Source: News